DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–11624]

Request for Nominations for Voting Members on a Public Advisory Committee; Tobacco Products Scientific Advisory Committee (TPSAC)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for members to serve on the Tobacco Products Scientific Advisory Committee (TPSAC), in the Center for Tobacco Products. FDA seeks to include the views of qualified individuals on its advisory committees and therefore encourages nominations of appropriately qualified candidates. Specifically, TPSAC is seeking to fill 2 voting member vacancies with physicians, dentists, scientists, or health care professionals practicing in the areas of oncology, pulmonology, cardiology, toxicology, pharmacology, addiction, engineering, or any other relevant specialty.

DATES: Nominations received on or before December 14, 2026 will be given first consideration for membership on the TPSAC. Nominations received after December 14, 2026 will be considered as later vacancies arise.

ADDRESSES: All nominations for membership should be sent electronically by logging into the FDA Advisory Committee Nomination Portal at *http://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm* and select ''Academician/Practitioner'' as the membership type. Nominations also may be submitted by mail to Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3215, Silver Spring, MD 20993–0002. Information about applying for membership is available at *https://www.fda.gov/advisory-committees/advisory-committee-membership/applying-membership-fda-advisory-committees.* Information about TPSAC, including committee charter and meeting materials, is available at *https://www.fda.gov/advisory-committees/committees-and-meeting-materials/tobacco-products-scientific-advisory-committee.*

Nominations submitted to the *Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees* notice published on October 1, 2026, will also be considered for the current vacancies.

FOR FURTHER INFORMATION CONTACT:

Regarding all nomination questions for membership, the primary contact is: Advisors and Consultants Staff (ACS), *CTP-OS-ACS@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting members on the TPSAC.

I. General Description of Committee Duties

The Tobacco Products Scientific Advisory Committee (TPSAC or the Committee) advises the Commissioner of FDA or designee in discharging responsibilities related to the regulation of tobacco products. The Committee reviews and evaluates safety, dependence, and health issues relating to tobacco products and provides appropriate advice, information, and recommendations to the Commissioner of Food and Drugs.

The Committee may provide recommendations to the Commissioner regarding any regulations to be promulgated under Section 917 of the Tobacco Control Act (TCA) and may review any applications for new tobacco products or petitions for exemption under Section 906(e) of the FD&C Act. The Committee may consider and provide recommendations on any other matter as provided in the Family Smoking Prevention and Tobacco Control Act.

II. Criteria for Voting Members

The Committee consists of a total of 12 members of whom there are nine, technically qualified, voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among physicians, dentists, scientists, or health care professionals practicing in the areas of oncology, pulmonology, cardiology, toxicology, pharmacology, addiction, or any other relevant specialty. Members and the Chair are selected from individuals knowledgeable in the fields of medicine, medical ethics, science, or technology involving the manufacture, evaluation, or use of tobacco products. One member shall be an officer or employee of a state or local government or of the Federal Government. The final voting member shall be a representative of the general public. Almost all non-Federal members of this committee serve as Special Government Employees. Members will be invited to serve for terms of up to 4 years.

III. Nomination Procedures

Any interested person may nominate one or more qualified individuals for membership on the advisory committee. Self-nominations are also accepted. Nominations must include a current, complete résumé or curriculum vitae for each nominee. Nominations must also specify the advisory committee for which the nominee is recommended. Nominations must also acknowledge that the nominee is aware of the nomination unless self-nominated. FDA will ask potential candidates to provide detailed information concerning such matters related to financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. 1001) and 21 CFR part 14, relating to advisory committees.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–21027 Filed 10–14–26; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, PAR Panel: Preclinical and Translational Research in Neurodegenerative Diseases November 04, 2026, 09:00 a.m. to November 04, 2026, 08:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on October 07, 2026, 91 FR 64156, Doc. No. 2026–20558.

This meeting is being amended to change the meeting from a 2-day to a 1-day meeting on November 4, 2026, and to change the end time from 6:30 p.m. to 8:00 p.m. The meeting is closed to the public.

Dated: October 13, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–21099 Filed 10–14–26; 8:45 am]

BILLING CODE 4167–05–P